Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: Interim 2-year results from an ongoing 5-year follow-up study in Europe

European Journal of Dermatology

Volumn 15, Issue 5, 2005, Pages 374-381

  Gollnick, Harald ^a   Barona, Carlos Guillén ^b   Frank, Ronald G J ^c   Ruzicka, Thomas ^d   Megahed, Mosaad ^d   Tebbs, Veronica ^e   Owens, Mary ^f   Stampone, Patti ^f  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e 3M Drug Delivery Systems   (United Kingdom)

^f 3M COMPANY   (United States)

Author keywords

Imiquimod; Immune response modifier; Long term follow up study; Recurrence; Superficial basal cell carcinoma

Indexed keywords

IMIQUIMOD; TOLL LIKE RECEPTOR 7;

ADULT; AGED; AORTA ANEURYSM; ARTICLE; BASAL CELL CARCINOMA; BURNING SENSATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PAIN; PHASE 3 CLINICAL TRIAL; PRURITUS; RECURRENT DISEASE; SKIN MANIFESTATION; SUPERFICIAL CANCER; TACHYCARDIA;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OINTMENTS; SKIN NEOPLASMS;

EID: 25144522269     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Marks R. The epidemiology of non-melanoma skin cancer: Who, why and what can we do about it. J Dermatol 1995; 22: 853-7.
2. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med 1992; 327: 1649-62.
3. MacKie RM. Basal cell Carcinoma Section of Epidermal skin tumours. In: Champion RH, Burton JL, Burns DA, Breathnach SM, eds. Textbook of Dermatology, Vol. 2, 6th ed. Oxford UK: Blackwell Science Ltd, 1998: 1679-84.
4. Slade HB, Owens ML, Tomai MA, Miller RL. Imiquimod 5% Cream (Aldara™). Exp Opin Invest Drugs 1998; 7: 437-49.
5. Testerman TL, Gerster JF, Imbertson LM, et al. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leuk Biol 1995; 58: 365-72.
6. Cornell RC, Greenway HT, Tucker SB, et al. Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 1990; 23: 694-700.
7. Toma S, Vincenti M, Palumbo R, et al. Results of the association of intralesional recombinant alpha interferon-2a (α-IFN) plus 13-cisretinoic acid (13cRA) in the treatment of basa cell carcinomas (BCC) of the skin. Int J Oncol 1993; 3: 1149-54.
8. Greenway HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, Nagi C. Treatment of basal cell carcinoma with interlesional interferon. J Am Acad Dermatol 1986; 15: 437-43.
9. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44: 807-13.
10. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47: 390-8.
11. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing lowfrequency dosing with and without occlusion. Br J Derm 2002; 147: 1227-36.
12. Lang PG, Maize JC. Basal Cell Carcinoma. Chapter 4. In: Friedman RJ, Rigel D, Harris MN, Baler D, eds. Cancer of the Skin. Philadelphia, PA: WB Saunders Company, 1991: 35-73.
13. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124: 869-71.
14. Cantor AB, Shuster JJ. Parametric vs. non-parametric methods for estimating cure rates based on censored survival data. Stat Med 1992; 11: 931-7.
15. Hemmi H, Kaisho T, Takeuchi O, Sato S, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196-200.
16. Schön M, Bong AB, Drewniok C, et al. Tumorselective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Nat Cancer Inst 2003; 95: 1138-49.
17. Ambach A, Bonnekoh B, Nguyen M, Schon MP, Gollnick H. Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro. Mol Immunol 2004; 40: 1307-14.
18. Gaspari AA, Sauder DN. Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol Surg 2003; 29: 1027-34.
19. Schön MP, Schön M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 2004; 9: 291-8.
20. Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003; 139: 1325-32.
21. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle controlled studies. J Am Acad Dermatol 2004; 50: 722-33.
22. Rowe DE, Carroll RJ, Day CL. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15: 315-28.
23. Thissen M, Neumann M, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 1999; 135: 1177-83.
24. Bath-Hextall F, Bong J, Perkins W, et al. Interventions for basal cell carcinoma of the skin: systemic review. BMJ 2004; 329(7468): 705.